CoChat

GLP-1 agonists and exercise: the future of lifestyle prioritization

Open access
Codella, Roberto, Senesi, Pamela, Luzi, Livio · 2025 · Frontiers in Clinical Diabetes and Healthcare

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index; 112 of the 164 sources its claims cite were checked for support.

Abstract

Recent literature shows that GLP-1 receptor agonists are highly effective for weight loss and improving metabolic and cardiovascular health, often surpassing the results of lifestyle interventions alone, such as exercise and diet modification. However, long-term weight maintenance is more successful when exercise is included, as stopping GLP-1 therapy alone often leads to weight regain, while exercise helps preserve muscle mass and sustain weight loss. Combining GLP-1 receptor agonists with structured lifestyle changes, especially increased protein intake and strength training, can mitigate muscle loss and enhance overall outcomes. As a result, future obesity management is likely to prioritize integrated approaches that combine pharmacotherapy with lifestyle interventions, rather than replacing lifestyle changes with medication alone.

Overview

CoChat Summary

## TL;DR

This narrative mini-review argues that GLP-1 receptor agonists are highly effective for weight loss and cardiometabolic benefit, but exercise remains essential for preserving lean mass and sustaining weight loss. The paper’s central conclusion is that future obesity care should prioritize hybrid approaches combining pharmacotherapy with structured lifestyle intervention rather than medication alone.

## Key findings

  • GLP-1RAs produce substantial weight loss, reported here as mean reductions of 7–9 kg over about a year, and can also improve BMI, waist circumference, blood pressure, lipid profiles, and cardiovascular outcomes.
  • In a cited STEP-1 semaglutide analysis, lean mass decreased by ~9.7% while fat mass fell by ~19.3%; in SURMOUNT-1 tirzepatide, about ~25% of total weight lost was lean mass and ~75% was fat mass over 72 weeks.
  • The paper states that GLP-1RAs generally yield greater short-term weight loss than exercise alone, but exercise is superior for maintaining lean mass and cardiorespiratory fitness.
  • Recent randomized trials cited in the review suggest that combining GLP-1RAs with exercise can add benefits, including improved maintenance of weight loss after stopping pharmacotherapy and reductions in metabolic syndrome severity, abdominal obesity, oxidative stress, and inflammation.

## Methods

  • This is a mini-review/narrative review, not an original empirical study.
  • The authors report a targeted literature search in PubMed/MEDLINE and Scopus from January 2015 to August 2025 using terms related to GLP-1 receptor agonists, exercise, obesity, type 2 diabetes, and weight loss.
  • Included evidence consisted of peer-reviewed randomized controlled trials, meta-analyses, and high-quality narrative/systematic reviews in English; preclinical/mechanistic studies were selectively included when they provided mechanistic insight.

## Limitations

  • The paper states that the evidence base has no standardized exercise protocols, with wide variability in training type, frequency, intensity, and supervision.
  • It also states that most trials have short follow-up periods, generally ≤6–12 months, and that heterogeneous body-composition measures and endpoints limit synthesis.
  • Evident from the text: this review is narrative rather than systematic, so its conclusions depend on a targeted search and selective inclusion of studies, which may increase the risk of bias; the paper also explicitly notes a likely publication bias toward positive/synergistic findings.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fcdhc.2025.1720794

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Combined effects of GLP-1RAs and exercise on weight and muscle health. GLP-1Ras promote significant weight loss and cardiometabolic benefits but may reduce skeletal muscle integrity. Exercise supports muscle maintenance and function, though its impact on weight is modest. A combined approach may maximize weight reduction while preserving lean mass.
Figure 1 Combined effects of GLP-1RAs and exercise on weight and muscle health. GLP-1Ras promote significant weight loss and cardiometabolic benefits but may reduce skeletal muscle integrity. Exercise supports muscle maintenance and function, though its impact on weight is modest. A combined approach may maximize weight reduction while preserving lean mass.CC BY · PubMed Central

Verification

Claims the paper makes

50 Valid · 3 Not valid · 9 Not checked · 10 Own results and interpretations

21 more claims · 14 with their cited sources checked

Create a free account to see all 72 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 44
  • Probably not a substantial claim. 3

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 64 references

Research works printed but not linked: 1

  1. Ozemek, 2026, ACSM’s guidelines for exercise testing and prescription, 645 p

Cited by

See all 16

Metadata

Authors
Codella, R., Senesi, P., & Luzi, L.
Affiliations
  • University of Milan (IT)
  • MultiMedica (IT)
Corresponding author
Codella, Roberto
Venue
Frontiers in Clinical Diabetes and Healthcare
Published
2025-11-24
Volume
6
Pages
1720794-1720794
ISSN
2673-6616 (ISSN-L)
OpenAlex
W4417230669
Cited by
16
References
64
Citations by year
2026: 16
FWCI
2.17
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Clinical Diabetes and Healthcare (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Ministero della Salute
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
GLP-1 receptor agonists, physical activity, obesity treatment, weight loss, weight maintenance, weight regain, muscle mass preservation, protein intake, resistance training, lifestyle intervention, pharmacotherapy, metabolic health, cardiovascular health

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 agonists and exercise: the future of lifestyle prioritization. https://app.cochat.ai/papers/10.3389/fcdhc.2025.1720794
The paper
Codella, R., Senesi, P., & Luzi, L. (2025). GLP-1 agonists and exercise: the future of lifestyle prioritization. Frontiers in Clinical Diabetes and Healthcare. https://doi.org/10.3389/fcdhc.2025.1720794

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.